预约演示
更新于：2026-02-27
Elexacaftor
更新于：2026-02-27
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H34F3N7O4S |
InChIKeyMVRHVFSOIWFBTE-INIZCTEOSA-N |
CAS号2216712-66-0 |
关联
4
项与 Elexacaftor 相关的临床试验NCT05822102
Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY
The purpose of this study is to support the clinical validation of a new assay to measure the levels of ivacaftor, tezacaftor, and elexacaftor (the components of Trikafta) in the bloodstream in order to achieve greater understanding of the effectiveness of this medication in all people with cystic fibrosis. Blood will be drawn at 3.0, 4.5, and 6.0 hours after taking the medication in the morning.
开始日期2023-02-09 |
申办/合作机构 |
NCT05675592
Linking Elexacaftor/Tezacaftor/Ivacaftor to Infections in Cystic Fibrosis Lung Disease
The goal of this observational study o is to define whether, how and to what extent treatment with Trikafta/Kaftrio directly affects Pseudomonas aeruginosa in individuals with cystic fibrosis. The main questions it aims to answer are:
* whether Trikafta/Kaftrio affects the bacterial phenotypes and susceptibility to antibiotics;
* whether Trikafta/Kaftrio impacts the bacterial virulence. Participants will be asked the permission to store and analyze P. aeruginosa isolates collected from respiratory samples for usual care plans before the initiation of treatment with Trikafta/Kaftrio and after 12 and 18 months of treatment. The results of bacterial analysis will be matched with clinical data at the specific time-points.
We expect to define effects of Trikafta/Kaftrio on P. aeruginosa and identify bacterial phenotypes as possible risk factors for its efficacy.
* whether Trikafta/Kaftrio affects the bacterial phenotypes and susceptibility to antibiotics;
* whether Trikafta/Kaftrio impacts the bacterial virulence. Participants will be asked the permission to store and analyze P. aeruginosa isolates collected from respiratory samples for usual care plans before the initiation of treatment with Trikafta/Kaftrio and after 12 and 18 months of treatment. The results of bacterial analysis will be matched with clinical data at the specific time-points.
We expect to define effects of Trikafta/Kaftrio on P. aeruginosa and identify bacterial phenotypes as possible risk factors for its efficacy.
开始日期2022-02-22 |
申办/合作机构 |
DRKS00023862
Impact of CFTR-modulation with elexacaftor/tezacaftor/ivacaftor on the exercise capacity, intestinal and respiratory microbiome, microbial and inflammatory metabolites in cystic fibrosis - IMMProveCFInflammation, Microbiome, Metabolome and physical Performance in Cystic Fibrosis
开始日期2021-05-04 |
申办/合作机构- |
100 项与 Elexacaftor 相关的临床结果
登录后查看更多信息
100 项与 Elexacaftor 相关的转化医学
登录后查看更多信息
100 项与 Elexacaftor 相关的专利（医药）
登录后查看更多信息
923
项与 Elexacaftor 相关的文献（医药）2026-05-01·Respiratory Medicine and Research
Skin side-effects of elexacaftor-tezacaftor-ivacaftor: a real-world view
Article
作者: Sunil, Devika ; Phillips, Mirain ; Darby, Alice ; Constantinou, Sophie ; Webber, Lucy ; Goodwin, Richard ; Duckers, Jamie
BACKGROUND:
Since 2020, ETI (elexacaftor/tezacaftor/ivacaftor) has been used to treat patients with cystic fibrosis. Acne and rash are listed as "common" and "very common" adverse effects in the Summary of Product Characteristics for ETI, affecting between 2-5% and 10% of patients respectively. Patients have, however, shared their experience of developing acne and rashes with clinicians and on social media. This study aimed to describe the real-world impact of rash and acne amongst patients taking ETI and to evaluate the service provided by healthcare practitioners.
METHODS:
A paper and/or electronic survey was distributed to adult patients taking ETI in two regional CF centres between November 2022 and February 2023.
RESULTS:
Of the 268 survey respondents, 20.9% reported new-onset acne and 13.8% reported a rash following the commencement of ETI. 11.9% had a past history of acne and reported an exacerbation/recurrence after starting ETI. ETI-associated acne occurred weeks to months after commencement of ETI, whereas most rashes occurred within the first 2 weeks of treatment. Reassuringly for 2/3 of affected patients, acne and rashes were minor side effects, although 1/3 experienced a greater impact on their quality of life.
CONCLUSION:
This study is the first to specifically report the real-world prevalence of acne and rashes amongst patients taking ETI, which is higher than that reported in clinical trials. These findings could be used to improve counselling of patients commencing ETI. Ensuring access to up-to-date resources and treatments for patients experiencing skin side-effects would be mutually beneficial for both patients and healthcare professionals.
2026-03-01·Paediatric Respiratory Reviews
Chalazion and hordeolum in paediatric patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor
Review
作者: Hunt, Sharon ; Boyton, Christie ; Fitzgerald, Dominic A ; Selvadurai, Hiran ; Simonds, Sharon ; Pandit, Chetan ; Solomon, Melinda ; Lieu, Nathan ; Singh, Jagdev
In the era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, we have seen impressive improvements to quality of life and life expectancy in people with cystic fibrosis (pwCF). However, there have been emerging adverse events related to elexacaftor/tezacaftor/ivacaftor (ETI). We present 8 paediatric pwCF who developed chalazion/hordeolum on standard dosing of ETI, of which one third needed interruption of ETI therapy to achieve resolution. This report highlights a 5.5-fold increased incidence of chalazion/hordeolum in pwCF and raises concerns of a clinical association between ETI and chalazion/hordeolum.
2026-03-01·ACTA PSYCHOLOGICA
Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice
Article
作者: Du, Jianyang ; Lu, Hui ; Reznikov, Leah R ; Fagan, Amy ; Ge, Qian
Recent advances in cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapies have markedly improved survival and quality of life for people with cystic fibrosis (CF). Among these, the elexacaftor-tezacaftor-ivacaftor combination (Trikafta) and vanzacaftor-tezacaftor-deutivacaftor (Alyftrek), represent major therapeutic milestones. However, emerging reports suggest that Trikafta may contribute to anxiety and depression in some people with CF. In this study, we investigated the neurobehavioral effects of elexacaftor and ivacaftor in mice. Acute administration of elexacaftor elicited anxiety-like behavior, while ivacaftor induced depressive-like behavior. Additionally, we confirmed the presence of Cftr mRNA in the amygdala and hippocampus, brain regions implicated in anxiety and depression. These findings provide preclinical support for the reported mental health side effects experienced by some people with CF and offer new insights into CFTR function within the central nervous system, potentially guiding the development of future CF therapies with improved neuropsychiatric profiles.
145
项与 Elexacaftor 相关的新闻（医药）2026-02-13
·药事纵横
在全球医药行业，年销售额超过100亿美元的药品堪称“超级重磅炸弹”，它们不仅是制药企业的核心增长引擎，更反映了全球疾病负担和医疗需求的变迁。2025年，全球医药市场见证了多款明星药物的卓越表现，尤其是GLP-1类药物在代谢疾病领域的爆发式增长，以及肿瘤免疫疗法和自身免疫疾病药物的持续强劲表现。以下是2025年销售额突破100亿美元的十大明星药品的详细分析。1. 替尔泊肽（365亿美元）：新一代“药王”的登顶
替尔泊肽是礼来公司开发的GLP-1/GIP双靶点受体激动剂，2025年以365亿美元的销售额成为全球新晋“药王”。这一成绩得益于其卓越的降糖和减重疗效，以及不断拓展的适应症范围。
替尔泊肽的成功源于其突破性的临床效果和市场策略。2025年，其降糖版销售额达229.65亿美元，同比增长99%；减重版销售额为135.42亿美元，同比激增175%。该药物已在美国获批用于糖尿病、减重和阻塞性睡眠呼吸暂停适应症，并于2025年1月获中国国家药监局批准用于代谢相关性脂肪性肝病，纳入突破性治疗品种名单。
替尔泊肽的爆发式增长凸显了全球代谢性疾病市场的巨大潜力。其第四季度表现尤为强劲，单季销售额突破116亿美元，预示着未来仍有增长空间。礼来公司预计2026年替尔泊肽将继续保持领先地位，公司全年营收指引为800-830亿美元。2. 司美格鲁肽（345亿美元）：GLP-1赛道的强劲竞争者
作为诺和诺德的王牌产品，司美格鲁肽2025年实现345亿美元的销售额，虽以微弱差距落后于替尔泊肽，但仍展现出强大的市场竞争力。
司美格鲁肽的优势在于其多元化的剂型布局。2025年，其降糖注射剂Ozempic销售额达1270.89亿丹麦克朗，减重注射剂Wegovy为791.06亿丹麦克朗，口服片剂Rybelsus为220.93亿丹麦克朗。特别是2025年12月获批的每日一次口服司美格鲁肽，进一步巩固了其在GLP-1市场的地位。
值得注意的是，司美格鲁肽在中国市场面临挑战，2025年总销售额为68.15亿丹麦克朗，仅比2024年上升了5%，Ozempic销售额还首次出现下滑。随着其核心专利将于2026年3月到期，多家国内药企已申报上市司美格鲁肽类似药，未来市场竞争将更加激烈。3. 帕博利珠单抗（317亿美元）：肿瘤免疫治疗的基石
默沙东的PD-1抑制剂帕博利珠单抗在2025年销售额达317亿美元，虽让出“药王”宝座，但仍是肿瘤治疗领域的绝对领导者。
帕博利珠单抗的成功得益于其广泛的适应症布局。自2014年上市以来，它已在全球获批超过40个适应症，涵盖非小细胞肺癌、宫颈癌、食管癌等多种肿瘤类型。2025年，该药物销售额首次突破300亿美元大关，占默沙东总收入的近50%。
面对2028-2029年的专利悬崖，默沙东正积极推动策略应对。公司开发了皮下注射制剂，预计到2028年渗透率可达30%-40%，并计划通过联合疗法和新适应症拓展，力争将销售额峰值提升至350亿美元。4. 阿哌沙班（234亿美元）：抗凝市场的领军者
百时美施贵宝和辉瑞联合开发的抗凝血药阿哌沙班2025年合计销售额达234.04亿美元，其中BMS销售144.43亿美元，辉瑞销售89.61亿美元。
阿哌沙班的持续增长源于其在预防卒中和非瓣膜性房颤血栓方面的优越疗效和安全性。尽管面临仿制药竞争，阿哌沙班2025年仍保持增长态势，BMS版销售额同比增长8%。该药物已成为抗凝治疗的金标准之一，在全球范围内拥有广泛的患者基础。
值得注意的是，阿哌沙班是前十明星药品中唯一的小分子单方药物，其成功体现了在生物药主导的重磅炸弹市场中，小分子药物仍可凭借显著的临床优势和市场需求保持竞争力。5. 度普利尤单抗（177亿美元）：自免领域的新王者
赛诺菲与再生元联合开发的度普利尤单抗2025年销售额达157.14亿欧元，按当年平均汇率计算约合177亿美元（再生元公布的数据为178亿美元），成为自身免疫疾病领域的新一代“药王”。
作为全球首个靶向IL-4Rα的单抗，度普利尤单抗已获批用于特应性皮炎、哮喘、慢性阻塞性肺疾病等8种适应症，覆盖从婴儿到老年人的各个年龄段。2025年其销售额同比增长25.2%，全球有超过130万患者正在接受该药治疗。
度普利尤单抗的增长动力来自持续扩大的适应症和市场需求。赛诺菲计划将其扩展至第9个适应症，并在全球范围内加速推广新获批的适应症。不过，该药也面临艾伯维的利生奇珠单抗的激烈竞争，后者以近50%的增速紧追不舍。6. 利生奇珠单抗（176亿美元）：迅速崛起的自免新星
艾伯维的IL-23抑制剂利生奇珠单抗2025年销售额达176亿美元，同比增长49.9%，成为自身免疫疾病领域增长最快的药物之一。利生奇珠单抗的成功得益于其在炎症性肠病领域的卓越表现。在美国市场，该药覆盖近半数克罗恩病患者和三分之一溃疡性结肠炎患者。2025年，其新患者启动率达40%-50%，契合全球炎症性肠病市场15%的年扩容速度。
利生奇珠单抗与乌帕替尼共同构成艾伯维的“免疫双子星”，2025年合计销售额达258.66亿美元，已超越修美乐历史巅峰时期的销售额。艾伯维预计这两款药物将成为2026年的核心增长驱动力，合计年收入有望突破310亿美元。7. 达雷妥尤单抗（144亿美元）：多发性骨髓瘤治疗的标杆
强生开发的达雷妥尤单抗2025年销售额为143.51亿美元，同比增长23%，连续多年跻身全球畅销药前十。
作为多发性骨髓瘤治疗的突破性药物，达雷妥尤单抗通过靶向CD38抗原发挥治疗作用。该药的成功巩固了强生在肿瘤领域的领导地位，也是其创新制药业务增长的主要驱动力之一。值得一提的是，强生与传奇生物合作的CAR-T疗法西达基奥仑赛同样表现亮眼，2025年收入达18.87亿美元，同比增长95.9%。这一组合进一步强化了强生在多发性骨髓瘤治疗领域的优势地位。8. Biktarvy（143亿美元）：HIV治疗的黄金标准
吉利德科学的Biktarvy(比克恩丙诺片)是全球HIV治疗的一线方案，2025年销售额达143.34亿美元。作为每日一次的单片 regimen，Biktarvy凭借优异的疗效和耐受性，持续领跑抗HIV药物市场。
Biktarvy的成功得益于其强大的病毒抑制能力和高耐药屏障，以及便捷的给药方案。在全球HIV市场趋于成熟的背景下，Biktarvy仍保持稳定增长，彰显了其市场领导地位。吉利德通过持续的市场教育和患者支持项目，进一步巩固了该药的市场份额。9. 纳武利尤单抗（108亿美元）：PD-1抑制剂的开拓者
百时美施贵宝的纳武利尤单抗（OPDIVO）2025年销售额为108亿美元，其中BMS销售100.49亿美元，小野制药销售7.7亿美元（按全年平均汇率计算）。作为全球首个获批的PD-1抑制剂，纳武利尤单抗在肿瘤免疫治疗领域具有里程碑意义。
尽管面临帕博利珠单抗的激烈竞争，纳武利尤单抗仍在多个癌种中保持重要地位。BMS通过开发新的联合疗法和适应症，努力维持该药的市场份额。同时，公司正将重心转向新一代免疫肿瘤药物，如Opdualag收入增长28%至11.85亿美元。10.Trikafta/Kaftrio（103亿美元）：罕见病之星
2月12日，福泰制药（Vertex pharma）公布了2025年业绩，Trikafta/Kaftrio(ivacaftor/ tezacaftor/ elexacaftor)的销售额再创新高，达到了103.13亿美元，成功跻身全球销售额突破100亿美元的十大明星药物。
Trikafta/Kaftrio是用于治疗囊性纤维化（CF）的CFTR调节剂组合药物，是公司收入的绝对基石，该产品在2025年贡献了103.127亿美元的收入，稳居其产品线首位。凭借超过20年在CF领域的深耕，福泰的CFTR调节剂组合在其核心市场已可覆盖近95%的CF患者，确立了绝对的领导地位。该药物通过精准纠正CFTR蛋白功能，显著改善了患者的肺功能与生活质量，是当前CF标准治疗方案的支柱，持续为公司提供稳定且可预测的现金流。
尽管Trikafta/Kaftrio是全球最昂贵的药物之一，但由于囊性纤维化本身是一种罕见疾病，受限于患者群体规模，其销售额增长已显现出平台期迹象，2025年收入仅较2024年增长不到1亿美元。趋势与展望
2025年百亿美元明星药品榜单反映了全球医药市场的三大趋势：首先，GLP-1药物引领代谢疾病治疗革命，替尔泊肽和司美格鲁肽合计销售额达710亿美元，标志着代谢疾病已成为医药行业最大的增长领域。其次，肿瘤免疫治疗进入成熟期，帕博利珠单抗和纳武利尤单抗合计销售额达425亿美元，但增长放缓预示市场临近峰值。最后，自身免疫疾病药物快速更迭，度普利尤单抗和利生奇珠单抗的激烈竞争，体现了自免领域创新加速的态势。
未来几年，随着专利悬崖逼近和市场格局变化，这些明星药品将面临更多挑战。但可以肯定的是，它们将继续为全球患者提供重要的治疗选择，同时推动医药行业不断创新与发展。
立即扫码加入药事纵横交流群
2026-02-13
导读：文章概要
本文围绕支气管扩张症（支扩）的病因诊断展开系统分析，强调明确病因对精准治疗的核心价值。文章指出，尽管2021年和2024年我国相继发布支扩诊治及病因诊断专家共识，但临床实践中仍面临病因确诊率低、检测技术局限等挑战。作者提出建立“病因‑可治疗特征”整合诊断模式，依托中国支扩联盟队列数据构建本土化诊断体系，并通过多中心协作推进规范化临床路径，最终目标是建立适用于中国人群的个体化干预策略，改善患者长期预后。
一、支扩病因诊断的临床意义
🔵病因多样性与主导类型
支扩病因复杂，包括肺部感染（如结核病、非结核分枝杆菌、铜绿假单胞菌）、病毒感染、遗传性疾病（如α1‑抗胰蛋白酶缺乏症）、自身免疫病、变应性支气管肺曲霉病（ABPA）及免疫缺陷等。
国际队列研究显示，特发性与感染后病因为主要类型，中国支扩联盟数据显示感染后病因占比高达43.2%，其中结核相关病因占12.2%，与我国结核病高负担现状直接相关。
🔵对治疗与预后的影响
🫁精准治疗案例：囊性纤维化（CF）患者可通过靶向致病基因型的三联疗法（如elexacaftor/tezacaftor/ivacaftor）显著改善症状；铜绿假单胞菌（PA）定植患者经雾化妥布霉素（TIS）治疗可有效清除细菌并改善生活质量。
🫁治疗禁忌警示：重组人脱氧核糖核酸酶（rhDNase）可能增加非CF支扩患者急性加重风险，需避免使用。
🫁整合诊断模式：需结合“病因”与“可治疗特征”（如黏液清除障碍、慢性感染、气道炎症），从对症治疗转向对因根治。
✅核心观点：病因诊断是连接"对症治疗"与"对因根治"的关键桥梁，需建立"病因-可治疗特征"整合诊断模式。
可治疗病因与可治疗特征的区分：
🍀可治疗病因： 气道疾病、ABPA、NTM肺病、免疫球蛋白缺陷、自身免疫性疾病、反流相关疾病、气道阻塞 对因治疗
🍀可治疗特征：（病因无法特异性干预时）机制： ①黏液清除障碍②慢性感染③气道炎症
方法：①气道廓清术/高渗盐水/黏液溶解剂②吸入抗生素③大环内酯类药物/吸入皮质类固醇
二、支扩病因诊断的中国路径突破
🔵地域异质性与本土化数据
中国支扩联盟（BE‑China）队列研究显示，中国患者病因构成具有独特性：感染后病因占主导，结核相关病因比例显著高于欧美国家。因此，临床需强化感染史追溯（尤其是结核病史），并建立长期随访机制。
🔵规范化筛查路径
根据2024年《成人支气管扩张症病因学诊断专家共识》，所有患者需完成基础病因筛查（血常规、ABPA血清学、免疫球蛋白定量、胸部HRCT、肺功能、痰微生物培养等），再基于个体特征启动进阶检查（支气管镜、自身抗体谱等），以提升病因检出率。
🔵精准分型与治疗转化
基于病因分层（可治疗/其他/特发性）与可治疗特征，推动靶向疗法的本土临床转化，例如DPP‑1抑制剂HSK31858的Ⅱ期研究显示可减少急性加重，为支扩治疗提供新策略。
🔵慢性感染管理的中国进展
✅ERASE研究（2023年9月启动）：- 研究设计：IV期、多中心、2×2析因设计、随机双盲安慰剂对照- 目的：评估妥布霉素吸入溶液±口服环丙沙星对PA的根除率及安全性- 意义：为中国患者建立标准化PA根除路径提供关键依据
✅DPP-1抑制剂HSK31858：- 2025年3月公布II期临床结果（SAVE-BE研究）- 显著改善症状并减少急性加重- 中国首个支扩靶向炎症新靶点药物
三、支扩对因治疗的实践难点与对策
🔵疾病异质性与共病管理挑战
🏈多重病因叠加：支扩常合并多种疾病（如慢性阻塞性肺疾病、哮喘、心脑血管疾病），导致诊疗策略制定困难，且多数慢阻肺病新药试验排除支扩患者，缺乏循证依据。
🏈对策：加强共病临床研究，例如针对COPD‑支扩重叠（CBA）患者的专项研究，以优化综合管理方案。
🔵检测技术局限性
🏈遗传性病因假阴性：常规基因检测可能因范围有限或技术敏感度不足导致漏诊。例如，外显子组测序（ES）假阴性可通过数据重分析、短读长/长读长基因组测序（srGS/lrGS）及功能验证改善。
🏈诊断能力差异：基层医疗机构对特殊病原体（如烟曲霉）检测覆盖率低，需通过转诊至支扩联盟核心单位提升诊断水平。
🔵中国特色解决方案
🫁PA根除治疗：启动ERADE研究（雾化妥布霉素±环丙沙星），旨在建立标准化PA根除路径。
🫁遗传性支扩诊断：建议对临床高度疑似但基因检测阴性者进行多技术联合检测，并推广新生儿筛查（如CF）。
四、未来展望
中国支扩联盟已积累18,000余例患者数据，支扩被纳入国家“四大慢病”重大专项，为精准诊疗奠定数据基础。未来需通过多中心协作、规范化临床路径及创新疗法转化，建立基于中国人群特征的个体化干预策略，最终突破经验性治疗局限，改善患者长期预后。
🔴核心结论：
支扩病因诊断是精准治疗的前提，需结合本土化病因谱（如高比例感染后及结核相关病因），通过“病因‑可治疗特征”整合模式与技术创新（如多组学检测）提升诊断效能。中国在支扩病因研究与治疗实践中已取得进展，但需进一步解决共病管理、检测技术推广及新药研发等挑战，以实现从“规范化”到“精准化”的跨越。
五、文章学术价值与创新点
1. 理论创新
- 提出"病因-可治疗特征"整合诊断模式，超越传统单一病因分类思维
- 强调从"对症治疗"向"对因根治"的范式转变
2. 实践指导
- 明确中国支扩病因谱的独特性（结核后支扩高比例）
- 提供分层、可操作的诊断路径
- 介绍中国原创临床研究（ERASE、SAVE-BE）进展
3. 政策推动
- 体现中国支扩联盟（BE-China）的学术领导力
- 推动支扩从"被忽视的慢病"进入国家重大慢病防控体系
参考文献：
支气管扩张症的病因诊断：从常规筛查到精准干预的价值与挑战
作者： 徐金富（同济大学附属同济医院）、朱桂银（复旦大学附属华东医院）
发表：期刊 《中华结核和呼吸杂志》2026年2月第49卷第2期
临床研究
2026-02-12
·搜狐新闻
采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）导读凡默谷技术部挑选了2024年7月—2025年12月全球采用MonolixSuite软件发表或涉及MonolixSuite综述的部分应用文章。希望对您的业务或专业学习有所帮助。本公众号不提供文章的原文下载，如您想了解某篇文章的详情，请下载《采用MonolixSuite软件发表的部分参考文献汇总列表 2024年7月-2025年12月》PDF版文件，有对应文章的介绍链接。2024年7月-2025年12月 PDF版文献汇总列表下载(复制链接到浏览器）https://www.jianguoyun.com/p/DfVhFxUQ_a64Bxih9ZkGIAA访问密码：HdX0tA01中国用户发表的部分文章或涉及到的综述用于预测拓扑异构酶抑制剂ADC药物在小鼠及人体内的药代动力学、肿瘤生长抑制效应及毒性风险的 PBPK-PD 模型PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans西维来司他钠在中国重症肺炎患者中的群体药代动力学研究Population pharmacokinetics of sivelestat in Chinese patients with severe pneumoniaZhang X., Hu H., Li Z., Zhang P., Pan L., Wang L., Mao J., Li F., Zhang L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e70001亚胺培南在感染性实体瘤患者中的群体药代动力学：一项真实世界研究Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world studyXu T., Zou T., Zhang J., Li Z., Li F., Du J., Hao Z. Journal of Global Antimicrobial Resistance. 2025 45 (107-114)PopPK和PBPK模型指导美罗培南在重症患儿增强肾脏清除率下的剂量优化PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal ClearanceLiu Y., He H., Zhang S.-S., Zhou J., Zhu J.-W., Xu J., Miao H.-J., Chen J.-H., Hao K. Pharmaceutics. 2025 17:12 Article Number 1544达泊西汀在健康中国男性受试者中的群体药代动力学Population Pharmacokinetics of Dapoxetine in Healthy Chinese Male SubjectsPu L., Wu T., Bai F., Lu H., Wang Y., Gao Y., Qiu W. Journal of Clinical Pharmacology. 2025丙泊酚注射液的群体药代动力学研究进展陈浩，陈建恒，吕洁，严泽林，卞民亮，陆程灿.《临床药物治疗杂志》. 第24 卷 第1 期, 2026年1月02其他国家用户发表的部分文章或相关的综述基于模型的荟萃分析应用 MonolixSuite：针对纵向分类与连续数据的教程Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous DataBracis C., Taneja A., Lyauk Y.K., Barcomb H., de la Peña A., Cellière G.CPT: Pharmacometrics and Systems Pharmacology2026 15:2 Article Number e70158 高强度间歇性运动对二甲双胍在健康男性的药代动力学影响——基于PopPK模型的评估Effect of high-intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic modelNikolaidis S., Kosmidis I., Papadopoulos S., Lioupi A., Gandanidou M., Gika H., Dokoumetzidis A., Theodoridis G., Mougios V. British Journal of Pharmacology. 2026 183:3 (438-452) 抗胸腺细胞球蛋白在髓消性造血干细胞移植中的PopPK与最佳药物暴露Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantationGhazal H., Leuchter S., Ngo R., Kinzel M., Dabas R., DharmaniKhan P., Khan F.M., Jamani K., Li N., Kiang T.K., Storek J. Transplantation and cellular therapy. 2026 他克莫司口服混悬液在造血干细胞移植患儿中的PopPK及生物利用度研究Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplantBrstilo L., Ibarra M., Juliá A., Testard J., Salgueiro R., Mendoza A., Pérez C., Licciardone N., Marquet P., Staciuk R., Buontempo F., Schaiquevich P. British Journal of Clinical Pharmacology. 2026 92:1 (210-219) 从 AUC/MIC 到 AUCss 与 Cmin：通过模型引导米卡芬净在危重患者治疗中的精准给药的优化From AUC/MIC to AUCss and Cmin: Optimizing Micafungin Therapy in the Critically Ill through Model-Informed Precision DosingBerrah R., Saint Marcoux F., Monchaud C., Cointault O., Conseil M., Jaber S., Jung B., Woillard J.B. AAPS Journal2026 28:1 Article Number 18阿莫西林在人乳中的PopPK建模——ConcePTION 项目的一项贡献Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION projectBaklouti S., Rigourd V., Panchaud A., Nordeng H., Allegaert K., Annaert P., Huang M.-C., Monfort A., Guidi M., Gandia P. British Journal of Clinical Pharmacology. 2026重症监护病房（ICU）收治的医院获得性肺炎患者中，他唑巴坦联合哌拉西林给药的关键阈值目标达标率Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia含删失协变量和测量误差的广义线性混合模型及其在 HIV/AIDS 研究中的应用Generalized Linear Mixed Models with Censored Covariates and Measurement Errors, with Applications in HIV/AIDS StudiesGao S., Wu L. Statistics in Biosciences. 2025 17:3 (832-854)神经重症监护人群中左乙拉西坦给药方案的优化：Neuro-ARC 研究Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC StudyKharouba M., Cook A.M., Bastin M.L.T., Kutsogiannis D.J., Mahmoud S.H. Neurocritical Care. 2025 43:3 (887-901)结合人胎盘离体灌注数据与PBPK建模预测艾司西酞普兰、舍曲林和帕罗西汀在母亲及胎儿中的药物暴露Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic ModelingPréta L.-H., Bouazza N., Foissac F., Froelicher L., Urien S., Buth V., Benaboud S., Tréluyer J.-M., Lui G. Clinical Pharmacokinetics. 2025 64:12 (1843-1854)ADC药物的上市后评估：基于模型荟萃分析和临床效用指数方法支持临床概念验证Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index ApproachAsiimwe I.G., Chtiba N., Mouksassi S., Pillai G., Peter R.M., Yuen E., Pilla Reddy V. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:11 (1810-1822)基于全身动态 PET 微剂量给药数据建立人体格列吡嗪全身药代动力学预测模型Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in HumansComin L., Marie S., Ursino M., Zohar S., Tournier N., Comets E. Clinical Pharmacokinetics. 2025 64:11 (1709-1722)家庭接触者中 SARS-CoV-2 检测的时间动态：首次阳性检测时间、症状出现时间与病毒载量峰值时间的差异Temporal Dynamics of SARS-CoV-2 Detection in Household Contacts: Divergences Between Time to First Positive Test, Symptom Onset, and Maximum Viral Load成人肺移植受者术后早期霉酚酸PopPK及贝叶斯评估Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period抗中性粒细胞胞浆抗体（ANCA）相关性血管炎中利妥昔单抗诱导与维持治疗方案的比较：基于真实世界患者 ANCA 及丙种球蛋白水平的PK/PD分析Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patientspH 值对德拉沙星抗大肠杆菌等基因株抗菌活性的影响：针对不同染色体和质粒介导的氟喹诺酮类耐药机制的研究Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms头孢唑林在儿科心脏手术患者中作为预防用药的PopPK研究Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery比较 COVID-19 疫苗接种后未感染者和康复者随时间变化的中和抗体活性Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individualsPillis L., Caffrey R., Chen G., Dela M., Eldevik L., Liu H., McConnell J.P., Shabahang S., Varvel S.A. Scientific reports. 2025 15:1 (34800-)泼尼松龙在系统性红斑狼疮患者中的PopPK建模：暴露量与疾病活动度分析Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity利妥昔单抗治疗多发性硬化症临床预试验中的PK-PD建模：迈向个性化给药间隔的研究Pharmacokinetic–pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval采用PopPK模型优化危重症难治性和超难治性癫痫持续状态患者的苯巴比妥给药方案Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model妊娠对囊性纤维化女性患者中 elexacaftor、tezacaftor 和 ivacaftor 药代动力学的影响Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in cystic fibrosis womenMagnas P., Bouazza N., Foissac F., Froelicher-Bournaud L., Lui G., Carlier N., Da Silva J., Fesenbeckh J., Kanaan R., Honoré I., Martin C., Treluyer J., Tsatsaris V., Burgel P., Benaboud S. Journal of Cystic Fibrosis. 2025 24 Supplement 2 (S279a-S280)HIV 感染者中比克替拉韦的群体药代动力学：真实世界研究Population pharmacokinetics of bictegravir in real-world people with HIV社区获得性肺炎重症患者经持续输注高剂量头孢吡普后的肺内浓度研究Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia血管紧张素 II/血管紧张素 I 比值作为接受依那普利治疗的健康成年受试者和心力衰竭儿童患者群体建模的一项新的药效学参数Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with EnalaprilSteichert M., Cawello W., Burckhardt B.B., Suessenbach F.K., Laeer S. Pharmaceutics. 2025 17:10 Article Number 1345精确调整达托霉素给药剂量：3 种、2 种、1 种及 0 浓度取样方案比较Precision Daptomycin Dosing: Comparison of 3-, 2-, 1-, and 0-Concentration Sample StrategiesGiuliano S., Pai M.P., Angelini J., Flammini S., Martini L., Baraldo M., Tascini C. Pharmacotherapy. 2025 45:9 (540-546)针对接受肾脏替代治疗的危重患者的美罗培南和哌拉西林/他唑巴坦优化给药方案Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyRoberts J.A., Ulldemolins M., Liu X., et al. Intensive Care Medicine. 2025 51:9 (1628-1640)基于PopPK模型优化利奈唑胺给药方案：针对疑似或确诊革兰阳性菌败血症的血液肿瘤患者Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive SepsisZavřelová A., Merdita S., Žák P., Radocha J., Víšek B., Lánská M., Maláková J., Michálek P., Slanař O., Šíma M. Clinical and Translational Science. 2025 18:9 Article Number e70346IgG 编码 mRNA的多尺度机理药代动力学—毒代动力学（PK-TK）建模在基础研究到临床的应用：以抗 Claudin 18.2 抗体为例Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic-Toxicokinetic (PK-TK) Model: A Case Study With Anti-Claudin 18.2Desai D.A., Cristofoletti R. Clinical and Translational Science. 2025 18:9 Article Number e70356使用 SVG-101 群体药动学模型评估其合理的剂量选择Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selectionMo K.H., Chae D., Jung Y.S., Jin B.H., Keum D.H., Choi M.K., Cha J.S., Park M.S., Kim C.O. Translational and Clinical Pharmacology. 2025 33:3 (156-167)2 型糖尿病患者代谢年龄和实际年龄vs碘海醇药代动力学的相关性Correlation of Metabolic Age & Calendar Age to Iohexol Pharmacokinetics in Patients With Type 2 DiabetesAlikhani R., Hooper L., Matvekas A., Waltje A., Rothberg A., Pai M. Clinical Pharmacology in Drug Development. 2025 14 Supplement 1 (6-7)通过群体PK/PD模拟评估替格瑞洛给药剂量中断及恢复治疗（含或不含负荷剂量）的效果Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD SimulationMatsui H., Pham L.T.T., Adane E. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:5 (409-418)缬更昔洛韦预防巨细胞病毒感染的目标达成情况Target attainment of valganciclovir prophylaxis against cytomegalovirusWenker S., Van Hasselt C., Moes D., Märtson A. British Journal of Clinical Pharmacology. 2025 91 Supplement 1 (8-9)胺碘酮对心脏手术后患者中阿哌沙班药物暴露的影响：一项群体药代动力学研究Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery—A Population Pharmacokinetic StudyMorath B., Foerster K.I., Chiriac U., Zaradzki M., Hoppe-Tichy T., Schrey D., Burhenne J., Czock D., Karck M., Haefeli W.E., Wicha S.G. Clinical Pharmacokinetics. 2025 64:8 (1191-1201)非甾体抗炎药在山地超级越野跑者干血斑中的定量分析：PK模型对结果解读的贡献Quantitative analysis of nonsteroidal anti-inflammatory drugs in dried blood spot from mountain ultra-trail runners. Contribution of pharmacokinetic models for the interpretation of the resultsMashal M.S., Guitton J., Sallet P., Bourguignon L., Machon C. Drug Testing and Analysis. 2025 17:6 (825-833)比较不同胰岛素类型的疗效：健康受试者葡萄糖钳夹效应的PK-PD建模Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy VolunteersChang Y.C., Jusko W.J. Journal of Clinical Pharmacology. 2025 65:8 (999-1010)评估多重插补算法对PK模型性能的影响：一项基于模拟的研究Assessing the Impact of Multiple Imputation Algorithms on Pharmacokinetic Model Performance: A Simulation-Based StudyDuflot T., Fayette L., Konecki C., Seurat J., Feliu C., Scala-Bertola J., Djerada Z.AAPS Journal. 2025 27:4 Article Number 77量化影响常染色体显性肾小管间质肾病进展速度和严重程度的临床及遗传因素Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progressionRamesh S.S., Rogge M., Kidd K.O., Williams A.H., Yoon D.Y., Roignot J., Blakeslee K., Bleyer A.J., Kim S. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:4 Article Number 41甲氨蝶呤的治疗药物监测、PopPK建模及在儿童急性淋巴细胞白血病患者高剂量给药的外部验证Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic LeukemiaMaximova N., Calabrò P.F., Cangialosi A., Di Paolo A. Chemotherapy. 2025 70:3 (109-118)危重症儿童尿液生物标志物与头孢吡肟治疗目标达成的关联研究Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill ChildrenDownes K.J., Sharova A., Amajor V., Gianchetti L., Himebauch A.S., Fitzgerald J.C., Zuppa A.F. Pediatric Infectious Disease Journal. 2025 44:8 (749-754)Andalusian马体内静脉注射对乙酰氨基酚及其代谢物后的群体药代动力学和临床评估研究Population pharmacokinetics and clinical evaluation of intravenous acetaminophen and its metabolites in Andalusian horses预测妊娠期间他克莫司的游离浓度Predicting Unbound Tacrolimus Concentrations during PregnancyLeino A., Wilson N.K., Kataria A.D., Hebert M.F. American Journal of Transplantation. 2025 25:8 Supplement 1 (S204-)AEROfen：一项 I 期临床、开放标签、随机交叉研究方案，通过PK模型评估健康受试者中雾化芬太尼的给药效率—比较面部与鼻内给药途径AEROfen: protocol for a phase I, open-label, randomised crossover study evaluating the efficiency of nebulised fentanyl in healthy volunteers - comparing facial versus intranasal administration via pharmacometric modellingFollet C., Dumont A., Roussel M., Gillibert A., Boedard C., Quillard M., Ruault S., Vallin F., Donnadieu N., Nunes Ferreira D., Pereira T., Joly L.-M., Lvovschi V., Duflot T. BMJ Open. 2025 15:7 Article Number e091125超越线性模型的浓度- QT 分析Beyond the linear model in concentration‑QT analysisGéraldine Cellière, Andreas Krause, Guillaume Bonnefois, Jonathan Chauvin. Journal of Pharmacokinetics and Pharmacodynamics. (2025) 52:311型干扰素介导的系统性红斑狼疮炎症的综合机制模型An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusVolkova A., Sokolov V., Tettamanti F., Verma M., Ugolkov Y., Peskov K., Tang W., Kimko H. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:7 (1225-1235)PK/PD建模与蒙特卡洛模拟预测接受（缬）更昔洛韦治疗的儿科移植受者的巨细胞病毒载量Pharmacokinetic/Pharmacodynamic Modelling and Monte Carlo Simulations to Predict Cytomegalovirus Viral Load in Pediatric Transplant Recipients Treated with (val) GanciclovirKoloskoff K., Franck B., Benito S., Welzel J., Autmizguine J., Theoret Y., Briand A., Ovetchkine P., Woillard J.-B. Clinical Pharmacokinetics. 2025 64:7 (1061-1069)沙特阿拉伯儿童肝移植术后早期他克莫司药代动力学的一项回顾性分析A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation periodAlghanem A., Joharji H., Garaween N., Alenazi H., Alsaleh N.A., Broering D., Alshagrani M., Alhassan F., Albassam A.A., Alsultan A., Alsmari A. Pediatrics and Neonatology. 2025 66:4 (368-374)利用纵向患者报告结局轨迹预测非小细胞肺癌生存期Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer理解与优化剂量探索：从剂量模拟到剂量估算Understanding and Streamlining Dose Finding: From Dose Simulation to Dose EstimationBräm D., Bachmann F., Schropp J., Gotta V., Steffens B., van den Anker J., Pfister M., Koch G. Journal of Clinical Pharmacology. 2025 65:6 (731-741)基于模型的方法评估抗药物抗体对生物制剂药物暴露的影响：以 CD3 T 细胞双特异性抗体赛必妥单抗为例A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific CibisatamabSanchez J., Pierrillas P.B., Frey N., Lotz G.P., Jönsson S., Friberg L.E., Frances N. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:6 (1065-1076)基于治疗药物监测, 考察阿米卡星在教学医院患者中的群体药代动力学Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching HospitalSteffens N.A., Zimmermann E.S., Azeredo F.J., Linden R., Finatto L.J., Hahn R.Z., Schwarzbold A.V., Pacheco L.S., Brucker N. Antibiotics. 2025 14:6 Article Number 531辅助靶点的药效学评估：低分子量 PBP7/8 对β-内酰胺类药物抗碳青霉烯耐药鲍曼不动杆菌活性的影响Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiHo B.M., Jin J., Sanborn J.T., Nguyen T.D., Singh N., Cheng C., Nasief N.N., Carlino-MacDonald U., Tsuji B.T., Zhao Y., Chen L., Moya B., Russo T.A., Smith N.M.Pharmaceuticals. 2025 18:6 Article Number 918WS02.06 Elexacaftor/tezacaftor/ivacaftor在 2 至 5 岁儿童中的药代动力学及行为障碍发生情况WS02.06Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioural disorders in children aged 2 to 5 years oldTruong N.H., Benaboud S., Chouchana L., Bonnel A.-S., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J.-M., Gaudelus I.S., Foissac F., Modul-CF research group. Journal of Cystic Fibrosis. 2025 24 Supplement 1 (S5-)老年群体中皮下注射与静脉注射头孢曲松的药代动力学：PhASAge 研究Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone in an Older Population: The PhASAge StudyRoubaud-Baudron C., Fauchon H., Stanke-Labesque F.,et al. Open Forum Infectious Diseases. 2025 12:6 Article Number ofaf313感染后期植入的 SIV 前病毒存在于寿命较短的 CD4+ T 细胞中SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells一箭多雕：用于多适应症的肠溶型霉酚酸钠的PopPK模型及贝叶斯估算Killing several birds with one stone: A multi-indication population pharmacokinetic model and Bayesian estimator for enteric-coated mycophenolate sodiumFromage Y., Sayadi H., Koloskoff K., Marquet P., Labriffe M., Monchaud C., Woillard J.-B. British Journal of Clinical Pharmacology. 2025 91:5 (1396-1408)通过PopPL分析优化 1-3 级肥胖患者静脉注射利多卡因的给药方案Dosing optimisation of intravenous lidocaine in patients with class 1–3 obesity by population pharmacokinetic analysisTognolini A.R., Liu X., Pandey S., Roberts J.A., Wallis S.C., Jackson D., Eley V.A. Anaesthesia. 2025 80:5 (511-521)用于考察阿替洛尔与美托洛尔在营养不良大鼠体内吸收的迷你PBPK模型Minimal Physiologically-Based Pharmacokinetic Modeling of Atenolol and Metoprolol Absorption in Malnourished RatsKir F., Sahin S., Jusko W.J. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:3 (251-263) Article Number e115Elexacaftor/Tezacaftor/Ivacaftor在囊性纤维化儿科患者中的群体药代动力学研究Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisTruong N.H., Benaboud S., Bouazza N., Barboura M.,et al. Clinical and Translational Science. 2025 18:5 Article Number e70245比较妊娠妇女在惊厥前期使用 75 mg与 150 mg阿司匹林的效果Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsiaVinogradov R., Kavanagh O.N., Kamali F., Robson S. American Journal of Obstetrics and Gynecology. 2025 232:5 (e189-e190)克林霉素与利福平联合用药的剂量及给药途径Dosing and route of administration of clindamycin given in combination with rifampicinMagréault S., Berrah R., Kerroumi Y., Mimram L., Salmon D., Goulenok T., de la Selle A., Lefort A., Marmor S., Helali N.H., Zeller V., Jullien V. Clinical Microbiology and Infection. 2025 31:5 (832-838)舒更葡糖或新斯的明逆转维库溴铵诱导犬神经肌肉阻滞的速度：随机临床试验与药理学建模Speed of reversal by sugammadex or neostigmine after vecuronium-induced neuromuscular block in dogs: Randomized clinical trial and pharmacological modelingMartin-Flores M., Lorenzutti A.M., Markmann A.D., Araos J., Campoy L. Veterinary Anaesthesia and Analgesia. 2025 52:3 (328-337)阿昔洛韦及其主要代谢产物 9-羧甲氧基甲基鸟嘌呤在早期肝移植受者中的群体药代动力学及伐昔洛韦的安全性评估Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipientsKably B., Briard M., Francoz C., Roux O., Houhou N., Mackiewicz V., Peytavin G., Durand F., Lê M.P. Journal of Antimicrobial Chemotherapy. 2025 80:5 (1302-1308)一种用于治疗慢性乙型肝炎的衣壳蛋白装配调节剂作用的多尺度模型A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B左乙拉西坦药代动力学在真实世界中的患者间变异性Real-world interpatient variability in the pharmacokinetics of levetiracetamChykharivska A., Kagan L., Wagner M., Brunetti L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e13059接受连续性肾脏替代治疗的危重患者是否需要调整头孢洛林给药剂量？基于回顾性数据的头孢洛林PopPK模型及目标达成概率分析的剂量模拟Do Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Require Ceftaroline Dosage Adjustments? Ceftaroline PopPK Model and Dosage Simulations with the Probability of Target Attainment Analysis Based on Retrospective DataAdamiszak A., Pietrzkiewicz K., Bartkowska-Śniatkowska A., Smuszkiewicz P., Kusza K., Grześkowiak E., Bienert A. Antibiotics. 2025 14:4 Article Number 347胶质母细胞瘤患者中帕米帕利总药量及游离药量的PopPK建模：药物处置机制解析与给药方案优化Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing OptimizationWickramasinghe C., Kim S., Jiang Y., Bao X., Yue Y., Jiang J., Hong A., Sanai N., Li J. Pharmaceutics. 2025 17:4 Article Number 524美罗培南在严重细菌感染患者中的群体药动学与基于模型的给药方案优化Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infectionMurínová I., Švidrnoch M., Gucký T., Rezáč D., Hlaváč J., Slanar O., Šíma M. European Journal of Hospital Pharmacy. 2024 31:3 (253-258)万古霉素在越南儿科患者治疗药物监测中的PopPK建模及中点浓度便捷采样Population Pharmacokinetic Modeling and Convenient Sampling of Midpoint Concentration for Therapeutic Drug Monitoring of Vancomycin in Vietnamese Pediatric PatientsHai L.B., Kien P.C., Dua N.T., Hao N.T., Hung V.M., Hai N.T., Le J., Huong N.T.L. Pharmaceutical Sciences Asia. 2024 51:3 (241-249)影响万古霉素谷浓度的因素：沙特非重症监护患者的PopPK模型Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi PatientsOrvacabtagene Autoleucel, 一种自体 BCMA 导向的CAR-T 细胞产品在治疗复发/难治性多发性骨髓瘤患者中的PopPK研究Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple MyelomaHu H., Li Y., Piasecki J., Hosseyni D., Yan Z., Liu X., Ogasawara K., Zhou S., Cheng Y. Clinical Cancer Research. 2025 31:6 (1163-1171)建模分析表明，奈玛特韦-利托那韦治疗后出现的 SARS-CoV-2 病毒反弹，是由靶细胞得以保留与病毒清除不彻底共同导致的Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearancePhan T., Ribeiro R.M., Edelstein G.E., Boucau J., et al.Journal of Virology. 2025 99:3用于癌症药物PK-PD建模与模拟的多器官芯片Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulationsMohammed A.E., Kurucaovalı F., Okvur D.P. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:1 Article Number 1NX210c多肽在健康老年受试者中的安全性、耐受性及PK-PD关系研究：一项随机、安慰剂对照、双盲、多剂量递增试验Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study卡泊芬净在接受体外膜氧合治疗的危重患者中的PopPK研究——ASAP ECMO 研究Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO studyAbdul-Aziz M.H., Diehl A., Liu X., Cheng V., Corley A., Gilder E., Levkovich B., McGuinness S., Ordonez J., Parke R., Pellegrino V., Wallis S.C., Fraser J.F., Shekar K., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2025 69:2肾功能不全患者中哌拉西林剂量调整：无论是否接受肾脏替代治疗, 均需增加达到目标暴露量Dosing of Piperacillin in Altered Renal Function with and without Renal Replacement Therapy for Required Increased ExpositionSurat G., Dohmann E., Scherf-Clavel O., Kurlbaum M., Hagel S. Open Forum Infectious Diseases2025 12 Supplement 1 (S798-)重症成人鲍曼不动杆菌感染患者口服米诺环素的PK模型Phamacokinetic Model of Oral Minocycline in Critically Ill Adult Patients with Acinetobacter baumannii InfectionKoumaki V., Athanassa Z., Valsami G., Papakyriakopoulou P., Saitani E.-M., Marques S., Manioudaki S., Sakagianni A., Dokoumatzidis A., Tsakris A. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S801-)使用容积吸收微量采样法研究多器官功能障碍综合征危重患儿中的万古霉素群体药代动力学Vancomycin Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children with Multiple Organ Dysfunction SyndromeShiau J., Amajor V., Rhodes N.J., Zuppa A., Downes K.J., Takyi-Williams J., Wen B., Scheetz M.H. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S788-S789)粒细胞集落刺激因子的群体PK-PD建模以优化 CD34+细胞采集的给药剂量与给药时机Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell HarvestingXu Jiang, Jun Seok Cha, Byung Hak Jin, Choon Ok Kim, Dongwoo Chae. Clinical and Translational Science, 2025; 18:e70121基于PopPK模型，为接受血液透析的肥胖患者群体制定万古霉素负荷剂量个体化给药方案Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic modelPolášková L., Hartinger J.M., Murínová I., Michálek P., Slanař O., Šíma M. Journal of Chemotherapy. 2025 37:2 (121-129)考虑个体间变异的低维神经常微分方程在 Monolix 和 NONMEM 中的实现Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEMBräm D.S., Steiert B., Pfister M., Steffens B., Koch G. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:1 (5-16)瑞德西韦及其代谢物在健康受试者和肾功能不全患者中的药代动力学模拟Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment群体PK/PD分析证实 SB16 与参比药物地舒单抗具有生物相似性Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab肠溶阿司匹林胶囊与片剂在健康受试者群体中的PK-PD研究Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects结核病治疗中剂量精准的重要性The importance of getting the dose right in the treatment of tuberculosis瑞舒伐他汀和依折麦布联合用药导致肠肝循环的群体PK-PD研究Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe在美国未感染 HIV 的成人中单独使用抗HIV-1 单克隆抗体 PGT121.414.LS，及与VRC07-523LS 联合给药的安全性、耐受性、药代动力学及中和活性研究（项目编号HVTN 136/HPTN 092）：一项首次人体、开放标签、随机对照的 1 期临床试验Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialEdupuganti S., Hurt C.B., Stephenson K.E., Huang Y., et al.The Lancet HIV. 2025 12:1 (e13-e25)恩诺沙星在治疗肉鸡大肠杆菌病中的PK、PD预测指标及蒙特卡洛模拟研究Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens卡铂在犬类中的PopPK建模及其临床剂量调整Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogsBéguin J., Mahfoudhi S., Uzel M., Rostang A., Ibish C., Ferran A.A., Pelligand L., Hulin A., Kohlhauer M. BMC Veterinary Research. 2024 20:1 Article Number 575Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring ConcentrationsAl-Zubaydi F., Wassef A., Kagan L., Brunetti L. Pharmaceutics. 2024 16:12 Article Number 1514阿莫西林对犬类假中间葡萄球菌PK-PD评价Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against Staphylococcus pseudintermedius in DogsJeong J.-S., Kim J.-W., Kim J.-H., Kim C.-Y., Chung E.-H., Boo S.-Y., Lee S.-H., Ko J.-W., Kim T.-W. Pathogens. 2024 13:12 Article Number 1121膳食和制剂对耐药性发育性及癫痫性脑病患儿体内大麻二酚全身暴露的影响Impact of food and formulation on cannabidiol systemic exposure in children with drug-resistant developmental and epileptic encephalopathiesBrstilo L., Reyes G., Ibarra M., Cáceres Guido P., Bressan I., Marin M.N., Delaven S.F., Agostini S., Pérez Montilla C., López M.E., Cresta A., García Bournissen F., Schaiquevich P., Caraballo R. Epilepsia. 2024 65 Supplement 1 (492-)基于模型荟萃分析建立复方口服避孕药突破性出血模型Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysisChen H., Chun D., Lingineni K., Guzy S., Cristofoletti R., Hoechel J., Jiao T., Cicali B., Vozmediano V., Schmidt S. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:11 (2016-2025)静脉注射免疫球蛋白在治疗各类免疫系统疾病患者中的PopPK模型Population Pharmacokinetic Model of Intravenous Immunoglobulin in Patients Treated for Various Immune System DisordersLee J.L., Mohamed Shah N., Makmor-Bakry M., Islahudin F., Alias H., Mohd Saffian S. Clinical Therapeutics. 2024 46:12 (e25-e37)持续输注哌拉西林/他唑巴坦可优化择期盆腔摘除术患者术中抗生素暴露水平Continuous infusion of piperacillin/tazobactam optimizes intraoperative antibiotic exposure in patients undergoing elective pelvic exenteration surgeryJackson D., Ulldemolins M., Liu X., Harris C., Tognolini A., Wallis S.C., Sumi C., Parker S.L., Eley V., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2024 68:12接受单倍体相合干细胞移植并采用移植后环磷酰胺/环孢素 A 为基础的移植物抗宿主病预防方案的患者中，霉酚酸暴露量降低—需加强剂量调整Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose IntensificationPai A.A., Panetta J.C., Bijukumar N., Renji R.M., A M., Jayaraman A., Karumathil S., Korula A., Selvarajan S., Srivastava A., Abraham A., Mathews V., George B., Kulkarni U., Balasubramanian P. Blood. 2024 144 Supplement 1 (2150-)不同剂量的甲氨蝶呤在类风湿关节炎患者中的PK-PD建模与模拟Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis研究丙泊酚作为单一药物对 2-12 岁儿童双频谱指数峰值效应时间的影响Understanding time to peak effect of propofol as sole agent on bispectral index in children aged 2–12 yearsGavel G., Koch G., Terrier A., Atkinson A., Pfister M., Erb T. Paediatric Anaesthesia. 2024 34:10 (1019-1028)替扎帕林（一种皮下注射普通肝素的替代药物）用于重度及终末期肾功能不全患者的回顾性单中心观察性研究Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study麦考酚酸酯在印度狼疮性肾炎患者群体中的PopPK及有限采样策略研究Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus NephritisKoloskoff K., Panwar R., Rathi M., Mathew S., Sharma A., Marquet P., Benito S., Woillard J.-B., Pattanaik S. Therapeutic Drug Monitoring. 2024 46:5 (567-574)通过建模与模拟确定儿科重症监护室中美罗培南的最佳给药策略Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation给药剂量是否得当？重症儿童患者中头孢吡肟的PopPK研究Are We Dosing Correctly? Population Pharmacokinetics of Cefepime in Critically Ill Pediatric PatientsRolsma S., Blackman M., Beck C., Dbouk A., Morovia F., Glover F., Ess G., Dohler K., Bridges B., Choi L., Creech C.B. Journal of the Pediatric Infectious Diseases Society. 2024 13 Supplement 4 (S9-S10)评估高加索健康受试者中与体重相关的协变量对利福平PK的影响Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteersBilal M., Ullah S., Jaehde U., Trueck C., Zaremba D., Wachall B., Wargenau M., Scheidel B., Wiesen M.H.J., Gazzaz M., Chen C., Büsker S., Fuhr U., Taubert M., Dokos C. European Journal of Clinical Pharmacology. 2024 80:9 (1271-1283)采用非线性混合效应模型对肥胖血液透析患者庆大霉素个体药代动力学参数进行估算Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect modelLee H., Yoon S., Chung J.Y. Translational and Clinical Pharmacology. 2024 32:3 (150-158)利用定量药理学评估患者友好的伊维菌素 CHILD-IVITAB 在体重≥15 kg 和 <15 kg 儿童中的给药剂量Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kgGolhen K., Buettcher M., Huwyler J., van den Anker J., Gotta V., Dao K., Rothuizen L.E., Kobylinski K., Pfister M. Pharmaceutics. 2024 16:9 Article Number 1186Elexacaftor/tezacaftor/ivacaftor 药代动力学与 2 至 5 岁儿童行为障碍的发生情况的研究Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurance of behavioral disorders in children aged 2 to 5Truong N., Benaboud S., Chouchana L., Bonnel A., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J., Sermet-Gaudelus I., Foissac F. Journal of Cystic Fibrosis. 2024 23 Supplement 2 (S277-S278)重症患者需增加头孢哌酮负荷剂量：一项采用PK建模评估推荐负荷剂量的回顾性研究Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic ModellingLaunay M., Ollier E., Kably B., Le Louedec F., Thiery G., Lanoiselée J., Perinel-Ragey S. Antibiotics. 2024 13:8 Article Number 756达沙替尼在健康受试者中的PopPK研究Population Pharmacokinetics of Dasatinib in Healthy SubjectsHassouneh W.B., Al-Ghazawi M.A., Saleh M.I., Najib N. Pharmaceuticals. 2024 17:6 Article Number 671WS15.03 Elexacaftor/tezacaftor/ivacaftor 在囊性纤维化儿科患者中的PopPK研究WS15.03 Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in paediatric patients with cystic fibrosisTruong N.H., Benaboud S., Bardin E., et al. Journal of Cystic Fibrosis. 2024 23 Supplement 1 (S28-)慢性髓性白血病患者体重指数与血浆中伊马替尼浓度的关系，并采用PK引导的给药策略减轻其临床影响Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategyMaroselli P., Fanciullino R., Colle J., Farnault L., Rocher P., Venton G., Costello R., Ciccolini J. Journal of Clinical Oncology. 2024 42:16 Supplement延长纳武利尤单抗给药间隔：在未筛选癌症患者中开展基于模型的模拟Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patientsPuszkiel A., Bianconi G., Pasquiers B., Balakirouchenane D., Arrondeau J., Boudou-Rouquette P., Bretagne M.-C., Salem J.-E., Declèves X., Vidal M., Kramkimel N., Guegan S., Aractingi S., Huillard O., Alexandre J., Wislez M., Goldwasser F., Blanchet B. British Journal of Cancer. 2024 130:11 (1866-1874)RPEM：随机蒙特卡洛参数期望最大化算法RPEM: Randomized Monte Carlo parametric expectation maximization algorithmChen R., Schumitzky A., Kryshchenko A., Nieforth K., Tomashevskiy M., Hu S., Garreau R., Otalvaro J., Yamada W., Neely M.N. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:5 (759-780)肺移植受者进行伊沙康唑治疗药物监测的理论依据The Rationale for Therapeutic Drug Monitoring of Isavuconazole in a Lung Transplant RecipientZajacova A., Sima M., Havlin J., Klapkova E., Lischke R., Slanar O., Dvorackova E. Journal of Heart and Lung Transplantation. 2024 43:4 Supplement (S644-S645)Lumacaftor/Ivacaftor 在囊性纤维化儿科患者中的PopPK：迈向个体化治疗的第一步Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized TherapyBouazza N., Urien S., Foissac F., Choupeaux L., et al. Clinical Pharmacokinetics. 2024 63:3 (333-342)赖诺普利在高血压的儿童和正常至轻度肾功能受损的青少年的PopPK研究Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney functionSandra L., Degraeuwe E., De Bruyne P., De Baere S., Croubels S., Van Bocxlaer J.F.P., Raes A., Vande Walle J., Gasthuys E., Vermeulen A. British Journal of Clinical Pharmacology. 2024 90:2 (504-515)基于模型的临床前试验心血管安全性评估与转化教程A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsKulesh V., Vasyutin I., Volkova A., Peskov K., Kimko H., Sokolov V., Alluri R. CPT: Pharmacometrics and Systems Pharmacology2024 13:1 (5-22)提高奥拉帕利的药物暴露量以优化不良反应管理Improving olaparib exposure to optimize adverse effects managementSterlé M., Puszkiel A., Burlot C., Pereira E., Bellesoeur A., De Percin S., Beinse G., Fumet J.-D., Favier L., Niogret J., Blanchet B., Royer B., Bengrine-Lefevre L., Schmitt A. Therapeutic Advances in Medical Oncology. 2024 16疑似急性肾移植排斥反应：甲基泼尼松龙治疗下他克莫司的药代动力学研究Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone TherapyBidu N.S., Mattoso R.J.C., Santos O.A.C.O., Alves I.A., Fernandes B.J.D., Couto R.D. Current Drug Research Reviews. 2024 16:3 (403-411)►►►往年MonolixSuite文献汇总返回搜狐，查看更多
100 项与 Elexacaftor 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11507 | Elexacaftor | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 葡萄糖代谢紊乱 | 临床3期 | 荷兰 | 2020-11-09 | |
| 囊性纤维化 | 临床3期 | 荷兰 | 2018-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | - | - | 衊繭蓋遞遞製蓋網餘壓(繭衊製範鏇範艱獵簾壓) = 繭廠壓鹽鏇積遞願壓築 鏇築範鏇淵積鬱醖鬱窪 (製簾鬱醖繭簾積襯蓋繭 ) | - | 2025-05-16 | ||
衊繭蓋遞遞製蓋網餘壓(繭衊製範鏇範艱獵簾壓) = 構網憲鏇膚鏇網壓築範 鏇築範鏇淵積鬱醖鬱窪 (製簾鬱醖繭簾積襯蓋繭 ) | |||||||
N/A | 50 | 遞顧觸齋艱齋築衊觸廠(鹹鹹範願餘願淵鏇網鹹) = Patients with a low pre-treatment RV/TLC ratio showed higher responses after 12 months of ETI 糧衊窪衊齋蓋簾壓積餘 (構糧構艱艱製構遞願艱 ) | 积极 | 2023-09-09 | |||
Placebo | |||||||
N/A | 156 | 獵憲繭壓觸壓餘鹽繭顧(繭簾築願壓積構構鏇廠) = 艱蓋鏇艱壓構範鹹糧廠 構憲顧齋膚鏇糧觸鏇鑰 (襯鑰願遞積夢淵構壓繭 ) 更多 | 积极 | 2023-09-09 | |||
N/A | 45 | 繭築製鑰築願憲壓醖廠(積衊鹹簾蓋鏇醖鹹廠觸) = One patient was diagnosed with bipolar disorder 積鏇鑰艱獵憲夢膚獵觸 (簾醖膚鬱蓋廠選構鑰齋 ) 更多 | 不佳 | 2023-09-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用